Ultragenyx Pharmaceutical Inc
Insiders
Last 12 monthsSales planned on beside the trades reported on , and whether each names a .
Planned ·
$1,473,714
16 notices · 59,807 sh
Oct 2025 to Oct 2026
Reported ·
$3,612,524
23 sales · 0 buys
Oct 2025 to Jun 2026
The two figures cover different periods.
11 of 23 reported sales carry the 10b5-1 box. Together they are 0.15% of the shares on issue.
under a no plan named▼ salesize is dollars
Form 144 notices, newest first
2026-09-15THEODORE HUIZENGA, SVP, Chief Accounting Officer$17,462
2026-08-03HOWARD HORN, Chief Financial Officer$117,024
2026-07-01HOWARD HORN, Chief Financial Officer$155,645
2026-06-15KARAH PARSCHAUER, EVP and Chief Legal Officer$92,506
Form 4, 2026-06-15: sold 1,899 at $24.62 Form 4 ↗
2026-06-15CORAZON D. SANDERS, Director$50,100
Form 4, 2026-06-15: sold 2,000 at $25.05 Form 4 ↗
2026-06-01HOWARD HORN, Chief Financial Officer$110,602
Form 4, 2026-06-01: sold 4,653 at $23.77 Form 4 ↗
2026-05-18SHEHNAAZ SULIMAN, Director$144,189
Form 4, 2026-05-18: sold 5,740 at $25.12 Form 4 ↗
2026-05-01HOWARD HORN, Chief Financial Officer$116,607
Form 4, 2026-05-04: sold 4,683 at $24.90 Form 4 ↗
2026-04-01HOWARD HORN, Chief Financial Officer$98,203
Form 4, 2026-04-02: sold 4,683 at $20.97 Form 4 ↗
2026-03-10KARAH PARSCHAUER, EVP and Chief Legal Officer$79,526
2026-03-06KARAH PARSCHAUER, EVP and Chief Legal Officer$128,775
Form 4, 2026-03-10: sold 9,526 at $21.87 Form 4 ↗
2026-03-03HOWARD HORN, Chief Financial Officer$36,624
2026-03-02HOWARD HORN, Chief Financial Officer$70,302
Form 4, 2026-03-03: sold 10,044 at $22.65 Form 4 ↗
2026-02-02HOWARD HORN, Chief Financial Officer$72,117
Form 4, 2026-02-03: sold 3,061 at $23.56 Form 4 ↗
2026-01-02HOWARD HORN, Chief Financial Officer$71,946
Form 4, 2026-01-05: sold 3,150 at $22.84 Form 4 ↗